Novo Nordisk Capital Markets Day scheduled in London

Novo Nordisk has scheduled a Capital Markets Day for September 21, 2026, in London, running from 9:00 a.m. to 3:30 p.m. British time (10:00 a.m. to 4:30 p.m. Central European Time).^[1][2] According to the company's investor materials, Executive Management and other senior leaders will give "a comprehensive overview of the company's strategy, R&D pipeline, business operations and performance," with plenary presentations and question-and-answer sessions broadcast live and archived online.^[2]

The event falls a few months into a busy stretch of investor updates for the Danish drugmaker. Novo Nordisk reported first-quarter 2026 results on May 6, second-quarter results on August 4, and is scheduled to report results for the first three quarters of 2026 on November 4, ahead of full-year 2026 results on February 3, 2027.^[1] Earlier in 2026, the company also held a call on February 23 to share headline results from its REDEFINE 4 trial and hosted a research and development event tied to the American Diabetes Association's annual meeting on June 7.^[1]

Current Novo Nordisk chief executive Mike Doustdar has already made public appearances tied to the company's 2026 investor calendar. He took part in a fireside chat at the J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026, in his role as President and CEO.^[1] The sources reviewed for this story do not specify what new pipeline assets, if any, will be unveiled at the September Capital Markets Day, nor do they confirm whether this event marks his first such appearance as chief executive. Those details are not yet known from the materials available.

As of September 14, 2026, Novo Nordisk shares traded at 281.00 Danish kroner, up 4.55 kroner on the day, according to the company's investor relations page.^[2] The page lists a roster of investor relations contacts, including Michael Novod, Frederik Taylor Pitter, and others, for outside parties seeking more information ahead of the event.^[2]

Why it matters for patients

Capital Markets Day events are aimed at investors and analysts, not patients, but what companies say at them can shape what medicines eventually reach pharmacy shelves and at what pace. Novo Nordisk's pipeline update could touch on the future of semaglutide products such as Ozempic, Wegovy, and Rybelsus, as well as any earlier-stage drugs in development. For patients currently taking or considering a GLP-1 medication, these events sometimes signal how a company plans to prioritize research, manufacturing, or new formulations, which can affect availability and, over time, pricing and insurance coverage.

However, the sources here do not detail specific pipeline drugs, dosing plans, or new indications expected to be discussed on September 21. Anyone following the event for concrete clinical news, such as new trial results or approval timelines, should look for the specific data Novo Nordisk releases that day rather than assuming outcomes in advance.

What happens next

The Capital Markets Day is set for September 21, 2026, in London, with a live webcast available for those tracking the event remotely.^[1][2] After that, Novo Nordisk's next scheduled financial disclosure is for the first three quarters of 2026, due November 4, 2026, followed by full-year 2026 results on February 3, 2027.^[1] Details of what is actually announced during the Capital Markets Day, including any specific pipeline assets or financial targets, were not available in the sources reviewed for this story and will need to be confirmed once the event takes place.